The FDA has issued a statement warning that doses of Botox received by over 350 medical centers in the U.S. may have been produced outside of the country. In an official statement, the agency points to a firm called Canada Drugs that may have supplied non-FDA approved drugs.
"Medical practices that purchase and administer illegal and unapproved medications from foreign sources are placing patients at risk and potentially depriving them of proper treatment," the FDA said in a December 19 statement.
This is not, however, the FDA's first brush with Canada Drugs. Earlier this year the agency warned as many as 19 medical centers that doses of the cancer drug Avastin may have been counterfeit. Another three warnings later followed about the same drug. All of these are brands readily distributed through Canada Drug.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org